Josh Bloom in The New York Post, 5/3/13 "Searching for the wrong miracles"
The US pharmaceutical landscape has changed rapidly and radically over the past decade with dire consequences. Companies have exited en masse from research in traditional disease areas, plunging headfirst into cancer research.
The result: We re getting lots of new not-especially-valuable cancer drugs, and not getting new pharmaceuticals we need far worse in particular, new antibiotics to combat the nonstop emergence of resistant superbugs.
These bacteria are relentlessly growing more resistant to whatever few antibiotics are still effective in stopping them. They kill 90,000 Americans a year, and rising and threaten to turn our hospitals into death traps...[Read more].
